dc.contributor.author | Odera, Esther Brenda | |
dc.contributor.author | Kwobah, Charles | |
dc.contributor.author | Stone, Geren | |
dc.contributor.author | Some, Faraj | |
dc.date.accessioned | 2020-07-30T06:34:09Z | |
dc.date.available | 2020-07-30T06:34:09Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | https://doi.org/10.1177/2325957413508320 | |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/3202 | |
dc.description.abstract | Sickle cell disease (SCD) is a genetic disorder resulting from a mutation in the hemoglobin (Hb) gene. Sickle cell disease results in chronic anemia and a variety of acute and chronic complications that can lead to early mortality. A child with both SCD and HIV presents a management challenge, particularly in a resource-limited setting. In this case report, we describe the case of an 18-month-old Kenyan girl with SCD and HIV who developed a severe hypersensitivity reaction to first-line antiretroviral therapy (ART). Selecting an appropriate drug substitute for a child with SCD and HIV presents a management dilemma when the available options have problematic side effect profiles or are inaccessible or inappropriate according to national guidelines. The challenges in choosing an appropriate ART regimen for a child with SCD and HIV highlight the lack of data and scarcity of treatment options for pediatric patients. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage | en_US |
dc.subject | Sickle cell disease | en_US |
dc.subject | Antiretroviral therapy | en_US |
dc.subject | Comorbidity | en_US |
dc.title | Sickle cell disease and HIV: a case highlighting management challenges for children in a resource - limited setting. | en_US |
dc.type | Article | en_US |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |